Evidence map›Paper›PMID 29196657›Full record

ArticleNature communications2017

Alternative activation generates IL-10 producing type 2 innate lymphoid cells.

Corey R Seehus, Asha Kadavallore, Brian de la Torre, Alyson R Yeckes, Yizhou Wang, Jie Tang, Jonathan Kaye

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 187 citations in OpenAlex.

  1. Article
  2. Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. From Bench to Clinic: Advances in Anti-Inflammatory Therapies for Atherosclerotic Coronary Artery Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Corey R SeehusResearch Division of Immunology, Departments of Biomedical Sciences and Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Asha KadavalloreResearch Division of Immunology, Departments of Biomedical Sciences and Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Brian de la TorreResearch Division of Immunology, Departments of Biomedical Sciences and Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Alyson R YeckesResearch Division of Immunology, Departments of Biomedical Sciences and Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Yizhou WangGenomics Core Facility, Cedars-Sinai Medical Center, 8723 Alden Drive, Los Angeles, CA, 90048, USA.
Jie TangGenomics Core Facility, Cedars-Sinai Medical Center, 8723 Alden Drive, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0002-3991-2539
Jonathan KayeResearch Division of Immunology, Departments of Biomedical Sciences and Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA. kayej@csmc.edu.ORCID http://orcid.org/0000-0002-1634-9069
Cedars-Sinai Medical Center · US

Funding

TOX, A Novel Regulator of Thymocyte SelectionR01AI054977 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI KAYE, JONATHAN G · 2004 to 2021
$6.3M
Characterization of a novel innate lymphoid cell (ILC2) with regulatory potentialR21AI124209 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI KAYE, JONATHAN G · 2016 to 2017
$481k
NIAID NIH HHS R01 AI054977NIAID NIH HHS R21 AI124209
6 · The paper itself

Abstract

Type 2 innate lymphoid cells (ILC2) share cytokine and transcription factor expression with CD4

Indexed as

Immunity, InnateAnimalsCells, CulturedInterleukin-10Interleukin-13Interleukin-2LungLymphocyte ActivationLymphocytesMiceMice, Inbred C57BLTh2 CellsInterleukin-10Interleukin-13Interleukin-2

Identifiers

PMID29196657
PMCPMC5711851
OpenAlexW2768407817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.